Do you want to read an article? Please log in or register.
Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
Genitourinary Cancer
Related content
Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder
World J Urol.
Alanee S, Alvarado-Cabrero I, Murugan P, Kumar R, Nepple KG, Paner GP, Patel MI, Raspollini MR, Lopez-Beltran A, Konety BR
doi: 10.1007/s00345-018-2421-5.
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Genitourinary Cancer
Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma
Expert Opin Drug Metab Toxicol.
Patel R, Bock M, Polotti CF, Elsamra S
doi: 10.1080/
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Lancet.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group
doi: 10.1016/
Lung, Respiratory and Thoracic Cancer
Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study
J Thorac Oncol.
Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Aix SP, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L
doi: 10.1016/j.jtho.2018.08.2027.
Breast Cancer
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
doi: 10.1016/S1470-2045(19)30689-8.
Genomic characterization of response to chemoradiation in urothelial bladder cancer
Cancer.
Desai NB, Scott SN, Zabor EC, Cha EK, Hreiki J, Sfakianos JP, Ramirez R, Bagrodia A, Rosenberg JE, Bajorin DF, Berger MF, Bochner BH, Zelefsky MJ, Kollmeier MA, Ostrovnaya I, Al-Ahmadie HA, Solit DB, Iyer G
doi: 10.1002/cncr.30219.
Genitourinary Cancer
Atezolizumab: a PD-L1 blocking antibody for bladder cancer
Clin Cancer Res.
Inman BA, Longo TA, Ramalingam S, Harrison MR
doi: 10.1158/
RECOMMENDED
Breast Cancer
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol.
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S
doi: 10.1016/S1470-2045(20)30465-4.